Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05182905 · ClinicalTrials.gov registry record · Early Phase 1
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
A Early Phase 1 study of Glioblastoma and Glioblastoma Multiforme, sponsored by Nader Sanai.
- Active
- Registry status
- Early Phase 1
- Development phase
- 97
- Enrollment target
- 1
- Study location
NCT05182905 is a Early Phase 1 study of Glioblastoma and Glioblastoma Multiforme that is active but no longer recruiting, run by Nader Sanai. The registered enrollment target is 97 participants, below the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (10% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05182905, a Early Phase 1 study of Glioblastoma and Glioblastoma Multiforme, is active but no longer recruiting, sponsored by Nader Sanai.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 97 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, single-center Phase 0/1b study that will enroll at least 27 participants with recurrent WHO Grade 4 Glioma requiring re-radiation and approximately 35 participants with newly-diagnosed WHO Grade 4 glioma (nGBM). The trial will be composed of a Phase 0 component (subdivided into Arms A - C), and an expansion Phase 1b. Patients with tumors demonstrating a positive PK response in the Phase 0 component of the study will be eligible to graduate to an expansion phase that combines therapeutic dosing of AZD1390 plus standard-of-care fractionated radiotherapy (RT).
Conditions Studied
Interventions
- DRUG AZD1390
Study Locations (1)
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2026-12-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05182905
The ClinicalTrials.gov registry entry for NCT05182905 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (10% lower). The listed sponsor is Nader Sanai, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which AZD1390 is the first listed.
NCT05182905 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT05182905 about?
NCT05182905 is a clinical study titled "AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients". This is an open-label, single-center Phase 0/1b study that will enroll at least 27 participants with recurrent WHO Grade 4 Glioma requiring re-radiation and approximately 35 participants with newly-diagnosed WHO Grade 4 glioma (nGBM). The trial will be composed of a Phase 0 component (subdivided int...
What is the current status of trial NCT05182905?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 97 participants. The study started on 2022-05-27. Estimated completion is 2026-12-10.
What conditions does trial NCT05182905 study?
This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme, Glioma, Glioma, Malignant.
What interventions are being tested in trial NCT05182905?
The interventions under investigation include: AZD1390 (DRUG).
Who is sponsoring clinical trial NCT05182905?
This trial is sponsored by Nader Sanai, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05182905 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
Implantable Microdevice In Primary Brain Tumors
RECRUITING · Early Phase 1
-
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
RECRUITING · Early Phase 1
-
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
RECRUITING · Early Phase 1
-
Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma
RECRUITING · Early Phase 1
-
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.